Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

NICE turns down BMS' blockbuster Opdivo for urothelial carcinoma

pharmafileJuly 06, 2018

Tag: NICE , BMS , urothelial carcinoma

PharmaSources Customer Service